Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
|
|
AN2 Therapeutics, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/03/2023 |
4
| Aziz Kabeer (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Sold 83,337 shares
@ $16.28, valued at
$1.4M
Sold 15,764 shares
@ $16.28, valued at
$256.6k
Sold 4,770 shares
@ $16.07, valued at
$76.7k
Sold 902 shares
@ $16.07, valued at
$14.5k
|
|
| 10/03/2023 |
4
| Adjuvant Global Health Technology Fund, L.P. (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Sold 83,337 shares
@ $16.28, valued at
$1.4M
Sold 15,764 shares
@ $16.28, valued at
$256.6k
Sold 4,770 shares
@ $16.07, valued at
$76.7k
Sold 902 shares
@ $16.07, valued at
$14.5k
|
|
| 10/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 09/29/2023 |
4
| Adjuvant Global Health Technology Fund, L.P. (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Sold 707 shares
@ $16.07, valued at
$11.4k
Sold 134 shares
@ $16.07, valued at
$2.2k
Sold 7,160 shares
@ $16.11, valued at
$115.3k
Sold 1,356 shares
@ $16.11, valued at
$21.8k
|
|
| 09/29/2023 |
4
| Aziz Kabeer (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Sold 707 shares
@ $16.07, valued at
$11.4k
Sold 134 shares
@ $16.07, valued at
$2.2k
Sold 7,160 shares
@ $16.11, valued at
$115.3k
Sold 1,356 shares
@ $16.11, valued at
$21.8k
|
|
| 09/29/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/25/2023 |
4
| Adjuvant Global Health Technology Fund, L.P. (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Sold 336 shares
@ $16, valued at
$5.4k
Sold 64 shares
@ $16, valued at
$1k
|
|
| 08/25/2023 |
4
| Aziz Kabeer (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Sold 336 shares
@ $16, valued at
$5.4k
Sold 64 shares
@ $16, valued at
$1k
|
|
| 08/23/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/22/2023 |
4
| RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Bought 1,777,778 shares
@ $9, valued at
$16M
|
|
| 08/16/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/16/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Underwriting Agreement, between the Company, Cowen and Company, LLC, Leerink Partners LLC and Evercore Group L.L.C.",
"Opinion of Cooley LLP",
"AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock Menlo Park, CA - August 15, 2023 - AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the pricing of an underwritten offering of 7,777,778 shares of its common stock. The shares of common stock are being sold at a price of $9.00 per share, a premium from today's closing price. Investors who have agreed to purchase shares in the offering include RA Capital Management, TCGX, Frazier Life Sciences, Marshall Wace, Adage Capital Partners LP, Avidity Partners, Janus Henderson Investors and Surveyor Capital . The gross proceeds from the offering to AN2 are expected to be..." |
|
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 07/25/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 07/05/2023 |
SC 13G
| JANUS HENDERSON GROUP PLC reports a 5.1% stake in AN2 Therapeutics, Inc. |
| 06/09/2023 |
4
| Aziz Kabeer (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Granted 23,742 options to buy
@ $5.91, valued at
$140.3k
|
|
| 06/09/2023 |
4
| Zakrzewski Joseph S (Director) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Granted 23,742 options to buy
@ $5.91, valued at
$140.3k
|
|
| 06/09/2023 |
4
| FitzPatrick Margaret M (Director) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Granted 23,742 options to buy
@ $5.91, valued at
$140.3k
|
|
| 06/09/2023 |
4
| Wong Stephanie (Director) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Granted 23,742 options to buy
@ $5.91, valued at
$140.3k
|
|
| 06/09/2023 |
4
| Marks Gilbert Lynn (Director) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Granted 23,742 options to buy
@ $5.91, valued at
$140.3k
|
|
| 06/09/2023 |
4
| Martin Patricia A. (Director) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Granted 23,742 options to buy
@ $5.91, valued at
$140.3k
|
|
| 06/09/2023 |
4
| Spigelman Melvin K (Director) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Granted 23,742 options to buy
@ $5.91, valued at
$140.3k
|
|
| 06/09/2023 |
4
| Readnour Robin Shane (Director) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Granted 23,742 options to buy
@ $5.91, valued at
$140.3k
|
|
| 06/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/15/2023 |
4
| Easom Eric (CEO) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Bought 10,000 shares
@ $5.377, valued at
$53.8k
|
|
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 04/26/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/26/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/26/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/14/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/13/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 03/29/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
|
|
|